[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibrosis-myocardial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibrosis-myocardial":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100330767","validating-novel-non-contrast-cardiac-mri-imaging-in-haemodialysis-patients-100330767",false,"NCT03586518","Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients","Validating the Accuracy of Novel, Non-contrast, Cardiac Magnetic resOnaNce Imaging in Defining Myocardial FIbRosis in Patients With End-stage Renal Disease on haeModialysis: the CONFIRM Study","CONFIRM","Inclusion Criteria:\n\n* Prevalent haemodialysis patient (more than 3 months)\n* Active on the supportive care register with anticipated death in the subsequent 12 months\n* Able to give informed consent\n* Consent to donation of heart for research following death\n* Able to understand written and verbal explanations in English\n\nExclusion Criteria:\n\n* Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)\n* Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)\n* Unable to give informed consent\n* Unable to understand written and verbal explanations in English","ALL","18 Years",{"count":20,"type":21},9,"ESTIMATED","OBSERVATIONAL","There are currently no good ways of measuring levels of scarring in the hearts of patients with advanced kidney disease and patients on dialysis, although recent research has shown a new cardiac MRI technique, called native T1 mapping, may provide a solution to this. To assess the accuracy of this novel technique in dialysis patients, it is essential to undertake a study which compares native T1 mapping to actual levels of scarring in the hearts of patients on dialysis.",[25,26],"End Stage Kidney Disease","Fibrosis Myocardial",[28,29,30,31],"Cardiac MRI","Hemodialysis","Myocardial Fibrosis","Myocardial Inflammation","RECRUITING","2025-04-15",{"date":35,"type":36},"2025-04-18","ACTUAL",{"date":38,"type":36},"2019-11-03",{"date":40,"type":21},"2025-12-31",{"name":42,"class":43},"University of Leicester","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100457808","atrial-late-gadolinium-enhancement-in-patients-with-repaired-congenital-heart-disease-100457808","NCT05241418","Atrial Late Gadolinium Enhancement in Patients with Repaired Congenital Heart Disease","Inclusion Criteria:\n\n* Patients \\>13 years old with congenital heart disease referred for cardiac MRI and receiving gadolinium as part of routine clinical care or for pre-ablation planning will be included.\n\nExclusion Criteria:\n\n* Those with self-reported anxiety or claustrophobia and\u002For the presence of a permanent pacemaker or implantable cardioverter defibrillator will be excluded.","13 Years",{"count":53,"type":21},50,"In this research study the investigators want to learn more about how well the investigators can visualize scar tissue in the heart by MRI. In patients with congenital heart disease who need a procedure in the electrophysiology laboratory, how the MRI findings match the findings in the electrophysiology laboratory is not known. This study works to answer these questions. Participants will undergo a cardiac MRI as part of the routine clinical care that was ordered by their doctors and additional imaging by cardiac MRI will be performed.",[56,26,57],"Congenital Heart Disease","Fibrosis; Heart",[59,60,61,28,62],"Late gadolinium enhancement","3D late gadolinium enhancement","atrial late gadolinium enhancement","Congenital heart disease","2025-02-10",{"date":65,"type":36},"2025-02-13",{"date":67,"type":36},"2022-03-23",{"date":69,"type":21},"2029-06-30",{"name":71,"class":43},"Boston Children's Hospital",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100362020","cardiovascular-magnetic-resonance-guided-insertion-of-implantable-cardiac-defibrillator-in-dilated-cardiomyopathy-100362020","NCT03993730","Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy","CMR GUIDE DCM","Inclusion Criteria:\n\n* Age greater than\u002Fequal to 18 years old\n* Non-ischemic cardiomyopathy of dilated type\n* Left Ventricular Ejection Fraction \\\u003C 45%\n* Able and willing to comply with all pre, post and follow-up testing and requirements\n* On maximum tolerated doses of angiotensin converting enzyme (ACE) inhibitors (or Angiotensin Receptor Blockers(ARB) or Neprilysin Inhibitors) and Beta Blockers\n\nExclusion Criteria:\n\n1. Known coronary artery disease (CAD) (History of Myocardial Infarction or Significant Epicardial CAD on Angiography)\n2. Hypertrophic Cardiomyopathy\n3. Cardiomyopathy related to sarcoidosis\n4. Arrhythmogenic Right Ventricular Dysplasia\n5. Standard LGE CMR contraindications (e.g. severe claustrophobia, metal)\n6. Currently implanted permanent pacemaker and\u002For pacemaker\u002FICD lead\n7. Clinical indication for ICD or pacemaker or Cardiac Resynchronisation Therapy\n8. Contraindications to intravenous Gadolinium\n9. Severe renal insufficiency (eGFR\\\u003C 45mls\u002Fmin\u002F1.73m2 )\n10. New York Heart Association Heart Failure functional class IV\n11. Conditions associated with life expectancy \\\u003C1 year\n12. Pregnancy or in females of child-bearing potential, the non-use of accepted forms of contraception",{"count":80,"type":21},1880,"INTERVENTIONAL",[83],"NA","CMR GUIDE DCM is a randomized controlled trial with a registry for non-randomized patients.\n\nPatients enrolled will have non-ischemic cardiomyopathy (NICM) with mild to severe Left Ventricular (LV) systolic dysfunction with replacement fibrosis identified on Cardiac Magnetic Resonance (CMR).\n\n954 patients will be randomised from 50 sites across 4-6 countries worldwide to receive an implantable defibrillator (ICD) or implantable loop recorder (ILR).\n\nDevice and clinical follow-up will be performed at 3, 6, 12, 24, 36 months and at end of study.",[86,87,26],"Dilated Cardiomyopathy","Left Ventricular Systolic Dysfunction","NOT_YET_RECRUITING","2019-06-20",{"date":91,"type":36},"2019-06-21",{"date":93,"type":21},"2020-06",{"date":95,"type":21},"2026-06",{"name":97,"class":43},"Flinders University"]